Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD study of TD-1439 in healthy subjects
NCT02954263Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Nov 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing TD-1439 with Placebo (2 arms). Primary endpoint: Number of adverse events by severity. Started Nov 2016; status: completed.
02
Drugs
TD-1439
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02954263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954263.